Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Umberto Vitolo, Annalisa Chiappella et al.|The Lancet Haematology|2016Cited by 139
<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Gianluca Gaïdano, Davide Rossi et al.|Haematologica|2019Cited by 137
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Luca Arcaini, Marco Frigeni et al.|The Oncologist|2018Cited by 69
Prognostic impact of <i>TP53</i> mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trialAnnalisa Chiappella, Fary Diop, Claudio Agostinelli et al.|British Journal of Haematology|2021Cited by 39
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial ResultsMaurizio Martelli, Luca Ceriani, Giovannino Ciccone et al.|Journal of Clinical Oncology|2024Cited by 30